Artiva Biotherapeutics (ARTV) Equity Average (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Equity Average for 3 consecutive years, with $119.6 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 38.29% to $119.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $119.6 million through Dec 2025, down 38.29% year-over-year, with the annual reading at $148.3 million for FY2025, 1104.46% up from the prior year.
- Equity Average for Q4 2025 was $119.6 million at Artiva Biotherapeutics, down from $139.1 million in the prior quarter.
- The five-year high for Equity Average was $193.8 million in Q4 2024, with the low at -$182.9 million in Q2 2024.
- Average Equity Average over 3 years is $12.8 million, with a median of $62.3 million recorded in 2024.
- Peak annual rise in Equity Average hit 2711.04% in 2025, while the deepest fall reached 38.29% in 2025.
- Over 3 years, Equity Average stood at -$156.7 million in 2023, then soared by 223.66% to $193.8 million in 2024, then plummeted by 38.29% to $119.6 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $119.6 million, $139.1 million, and $158.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.